Could Confluence Genetics’ Cas-CLEAR platform open a new path for liver cancer therapy?
Confluence Genetics launches Cas-CLEAR, a Cas12a2 CRISPR platform designed to kill mutation-bearing cancer cells. Explore the evidence and risks.
Pharma & Biotech